Brokerages Set PAREXEL International Co. (PRXL) PT at $80.76
Shares of PAREXEL International Co. (NASDAQ:PRXL) have earned a consensus recommendation of “Hold” from the twelve ratings firms that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $80.76.
Separately, Zacks Investment Research upgraded PAREXEL International from a “hold” rating to a “buy” rating and set a $98.00 target price on the stock in a report on Thursday, August 31st.
A number of large investors have recently added to or reduced their stakes in PRXL. Public Employees Retirement System of Ohio raised its position in PAREXEL International by 4.5% in the first quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock valued at $108,000 after purchasing an additional 73 shares during the period. Oregon Public Employees Retirement Fund raised its position in PAREXEL International by 1.5% in the second quarter. Oregon Public Employees Retirement Fund now owns 18,820 shares of the medical research company’s stock valued at $1,636,000 after purchasing an additional 283 shares during the period. LS Investment Advisors LLC raised its position in PAREXEL International by 15.6% in the second quarter. LS Investment Advisors LLC now owns 4,182 shares of the medical research company’s stock valued at $363,000 after purchasing an additional 563 shares during the period. Aperio Group LLC raised its position in PAREXEL International by 17.1% in the second quarter. Aperio Group LLC now owns 12,452 shares of the medical research company’s stock valued at $1,082,000 after purchasing an additional 1,816 shares during the period. Finally, State Treasurer State of Michigan raised its position in PAREXEL International by 1.0% in the second quarter. State Treasurer State of Michigan now owns 20,900 shares of the medical research company’s stock valued at $1,816,000 after purchasing an additional 200 shares during the period. 87.45% of the stock is currently owned by institutional investors.
Shares of PAREXEL International (NASDAQ PRXL) traded down $0.02 during trading on Monday, reaching $88.08. The company had a trading volume of 7,021,100 shares, compared to its average volume of 1,041,144. PAREXEL International has a 52-week low of $51.16 and a 52-week high of $88.10. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.45 and a current ratio of 1.45.
PAREXEL International (NASDAQ:PRXL) last issued its earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.08. PAREXEL International had a return on equity of 19.95% and a net margin of 4.62%. The firm had revenue of $557.20 million for the quarter, compared to analysts’ expectations of $537.59 million. During the same quarter last year, the firm earned $0.94 earnings per share.
PAREXEL International Company Profile
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.
Receive News & Ratings for PAREXEL International Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Co. and related companies with MarketBeat.com's FREE daily email newsletter.